FDA clears GE's Advanced Lung Analysis package

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon
GE Healthcare has won FDA clearance for its next-generation Advanced Lung Analysis technology to help radiologists evaluate and assess nodules and other lesions in the lung.  

The FDA clearance included a new feature within AdvantageALA called digital contrast agent (DCA) that automatically highlights suspicious anatomical regions such as lung nodules to assist and complement the physician during the reading process.